Chengda Biotechnology Acquires Recombinant Quadrivalent Enterovirus Vaccine Technology for RMB 46 Million – Strengthening Its HFMD Vaccine Pipeline Beyond EV71

Liaoning Chengda Biotechnology Co., Ltd. (SHA: 688739) announced that it has signed a Recombinant Quadrivalent Enterovirus Vaccine Technology Transfer Agreement with Viltech (Beijing) Biotechnology Co., Ltd. Under the agreement, Chengda…

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.